Cytochroma gets $45M in third round

CompanyAmount/RoundLead InvestorsDescription
Cytochroma
Canada
$45 million
Third
Mitsubishi Tanabe Pharma Corporation

The money will be used to advance Cytochroma's portfolio of vitamin D-based therapeutics into mid- and late-stage clinical trials.

Tetraphase Pharmaceuticals
Massachusetts
$25M
First
Mediphase Venture Partners, CMEA Ventures, Fidelity Biosciences, Flagship Ventures and Skyline Ventures

Tetraphase will use the funding to support the advancement of several antibiotic drug candidates.

Celator Pharmaceuticals
New Jersey
$22.5M
Third
Domain Associates, Ventures West, Quaker BioVentures, TL Ventures, GrowthWorks Capital, and BDC Capital

The money will be used to finance mid-stage studies of CPX-351 for acute myeloid leukemia.

Sierra Neuropharmaceuticals
Colorado
$21.5M
First
HealthCare Ventures, Morgenthaler Ventures, and Sequel Venture Partners

Sierra, which is based in Colorado, plans to formulate drugs that can be delivered directly to the fluid around the brain in order to provide more effective treatment for severe CNS diseases like epilepsy, depression and schizophrenia.

Cytochroma gets $45M in third round

Suggested Articles

The CTAD presentation cleared up some questions about the dataset without delivering a telling blow for either side of the debate.

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.